Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effects of the Hypomethylating Agent Guadecitabine on Peripheral Blood Mononuclear Cell Methylomes and Immune Cell Populations in Small-Cell Lung Cancer Patients.

Pharmaceuticals (Basel, Switzerland)·2026
Same author

Pharmacokinetic Drug-Drug Interaction Potential of Oral Anticancer Drugs.

Clinical pharmacology and therapeutics·2026
Same author

Adverse COVID-19 experiences and physical and psychological outcomes in patients with lung cancer.

Palliative & supportive care·2026
Same author

Effects of the Hypomethylating Agent Guadecitabine on Peripheral Blood Mononuclear Cell Methylomes and Immune Cell Populations in Small-Cell Lung Cancer Patients.

bioRxiv : the preprint server for biology·2026
Same author

A phase I study targeting the APE1/Ref-1 redox signaling protein with APX3330: first clinical agent targeting APE1/Ref-1 in cancer.

The oncologist·2025
Same author

Protocol of a randomized trial of acceptance and commitment therapy for patient fatigue interference and caregiver burden in advanced gastrointestinal cancer.

Contemporary clinical trials·2025
Same journal

Microfluidic rare cell analysis beyond counting: workflow design from enrichment to multi-omics.

Lab on a chip·2026
Same journal

A sperm racetrack to separate sperm by swim speed.

Lab on a chip·2026
Same journal

Controlled encapsulation and droplet size prediction in two-step microfluidic double emulsions.

Lab on a chip·2026
Same journal

A particulate blood-mimicking fluid with physiological biconcave geometry for microscale hemorheology.

Lab on a chip·2026
Same journal

Multicellular sensor arrays fabricated by capillary stamping for pattern-based odor discrimination.

Lab on a chip·2026
Same journal

A real-time microfluidic surveillance system for multiplex detection of heavy metal contamination in wastewater.

Lab on a chip·2026
See all related articles

Related Experiment Video

Updated: Apr 17, 2026

Clinical Microfluidic Chip Platform for the Isolation of Versatile Circulating Tumor Cells
05:58

Clinical Microfluidic Chip Platform for the Isolation of Versatile Circulating Tumor Cells

Published on: October 13, 2023

1.8K

Circulating tumor cell detection using a parallel flow micro-aperture chip system.

Chun-Li Chang1, Wanfeng Huang, Shadia I Jalal

  • 1School of Mechanical Engineering, Purdue University, West Lafayette, IN 47907, USA. savran@purdue.edu.

Lab on a Chip
|February 18, 2015
PubMed
Summary
This summary is machine-generated.

This study presents a novel microchip system for isolating and detecting circulating tumor cells (CTCs) in blood. The technology successfully identified CTCs in most cancer patient samples, offering a promising tool for cancer diagnostics.

More Related Videos

Microfluidics-based High-throughput Circulating Tumor Cell Sorting and Single-cell Sequencing Technology
09:45

Microfluidics-based High-throughput Circulating Tumor Cell Sorting and Single-cell Sequencing Technology

Published on: November 14, 2025

1000
Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

11.3K

Related Experiment Videos

Last Updated: Apr 17, 2026

Clinical Microfluidic Chip Platform for the Isolation of Versatile Circulating Tumor Cells
05:58

Clinical Microfluidic Chip Platform for the Isolation of Versatile Circulating Tumor Cells

Published on: October 13, 2023

1.8K
Microfluidics-based High-throughput Circulating Tumor Cell Sorting and Single-cell Sequencing Technology
09:45

Microfluidics-based High-throughput Circulating Tumor Cell Sorting and Single-cell Sequencing Technology

Published on: November 14, 2025

1000
Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

11.3K

Area of Science:

  • Biomedical Engineering
  • Oncology
  • Microfluidics

Background:

  • Circulating tumor cells (CTCs) are crucial biomarkers for cancer metastasis and progression.
  • Accurate isolation and detection of CTCs are essential for personalized cancer treatment and monitoring.
  • Existing CTC detection methods face challenges in sensitivity, specificity, and throughput.

Purpose of the Study:

  • To develop and validate an integrated microchip system for efficient on-chip isolation and detection of CTCs.
  • To optimize system parameters, including flow rate and magnetic field strength, for maximal CTC capture and minimal non-specific binding.
  • To assess the system's performance in detecting spiked cancer cell lines and CTCs in patient blood samples.

Main Methods:

  • Integration of immunomagnetics, high-throughput fluidics, and size-based filtration on a microchip.
  • Antibody-functionalized magnetic beads for targeted capture of CTCs via surface antigens.
  • Parallel fluid flow and magnetic field for efficient CTC enrichment and detection.
  • Finite element method for modeling magnetic and fluidic forces, followed by experimental verification.

Main Results:

  • The system demonstrated high detection efficiency, capturing an average of 89% of spiked MCF-7 breast cancer cells.
  • CTCs were detected in 49 out of 50 blood samples from non-small cell lung cancer (NSCLC) and pancreatic cancer (PANC) patients.
  • Detected CTC counts ranged from 2 to 122 per 8 mL of blood, with a statistically significant difference observed in CTC counts between treated and untreated NSCLC patients.

Conclusions:

  • The developed microchip system offers a sensitive and efficient platform for CTC isolation and detection.
  • This technology has the potential to significantly advance cancer diagnostics and patient monitoring.
  • Further studies can explore the application of this system in other cancer types and for therapeutic response assessment.